Bristol-Myers, Sanofi revamp Plavix sales alliance (Update)

by Linda A. Johnson

(AP)—Bristol-Myers Squibb Co. and France's Sanofi SA said Wednesday that they are restructuring their longtime partnership selling popular heart medications, now that their sales are plunging due to widespread competition from generic versions.

The two drugmakers made tens of billions of dollars over the last decade or so selling Plavix, a blood thinner that was long the world's second-best-selling drug. The companies also shared revenue from blood pressure drug Avapro and a related drug called Avalide that also includes a diuretic, or water pill.

The three medicines, among the top sellers for both companies, all got generic competition in the U.S. this spring. They already had generic rivals in other countries.

Plavix alone brought New York-based Bristol-Myers and Paris-based Sanofi a combined $9.7 billion in sales last year, according to company financial reports.

Multiple generic versions of Plavix, taken by millions of people to prevent strokes and heart attacks, arrived in U.S. drugstores May 17. Bristol, which had marketed Plavix in the U.S., then offered patients coupons that sharply reduced their insurance copayment for Plavix, but most patients quickly defected to much-cheaper generic pills, called clopidogrel.

Bristol's Plavix sales plummeted 60 percent to $741 million in the second quarter, and they're expected to fall even more in the just-ended third quarter. Bristol is to announce its results for the quarter on Oct. 24; Sanofi is to report its results the next day.

Avapro and Avalide, known chemically as irbesartan and irbesartan/hydrochlorothiazide, generated a total of $2.62 billion in worldwide sales last year. The two blood pressure drugs got generic competition in the U.S. in March, and their sales have since declined.

The new agreement would return to Sanofi rights to sell the drugs in nearly all countries. Bristol-Myers would continue to sell Plavix in the U.S. through December 2019. It would receive royalties from Sanofi's sales of Avapro and Avalide worldwide and from sales of Plavix in all countries except the U.S. and Japan, through 2018.

The agreement, which requires approval by government regulators, would take effect on Jan. 1, 2013. At the end of 2018, Bristol is to get a payment of $200 million from Sanofi.

"Our alliance with Bristol-Myers Squibb has been extremely successful and value generating for both partners," Hanspeter Spek, Sanofi's president of global operations, said in a statement.

The revised agreement simplifies the partnership and allows each company to focus on priorities such as developing new drugs, the drugmakers said. The pact also resolves ongoing disputes between the partners, including Bristol-Myers paying Sanofi $80 million as compensation for the disruption in the U.S. supply of Avalide last year.

Like most other major drugmakers, Bristol-Myers and Sanofi have seen significant drops in revenue because of recent generic competition to multiple drugs whose patents have expired. This so-called patent cliff, along with the weak global economy and pressure to reduce prices from insurers and government health programs in Europe, China and the U.S., has pharmaceutical companies scrambling to develop new drugs or acquire rights to others from other companies.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA extends Plavix patent by 6 months to May 2012

Jan 25, 2011

(AP) -- The makers of Plavix, the world's second best-selling medication, said Tuesday they will retain exclusive U.S. marketing rights to the blood thinner for an additional six months, under a decision by U.S. health regulators.

Generic versions of plavix approved

May 18, 2012

(HealthDay) -- The first generic versions of Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration.

FDA says heartburn drugs can interfere with Plavix

Nov 17, 2009

(AP) -- Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack ...

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.